Indications Awaiting (12.17.21)
There's good news and bad news in rheumatology fellowship matching for 2022. There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine.
Certain Cancers Increased with Autoimmune Diseases
Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased ris
T2T Debate - A Prologue with Dr. Marty Bergman
Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.
Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.
ACR21 Best Abstracts - Day 4
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these as their favorite reports:
Infection or Disease Flare: What Tools Can Help Differentiate?
Differentiation between a flare of disease and infection in patients with autoinflammatory (AI) conditions, where fever is the hallmark, can be extremely difficult. Promptly distinguishing between the two is of extreme importance in AI patients with compromised immune systems, often receivi
ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Day 1 Report from ACR21
The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our
Opening Day Report
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
RheumNow Podcast – ACR Convergence Begins (11.5.2021)
Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.
Industry Abstract Previews #ACR21 - Horizon, Aurinia, AstraZeneca
The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021. Below is a listing of some of their best studies for you to review and look for in the meeting.
RheumNow Podcast – Like Father, Like Daughter (10.29.2021)
Dr. Jack Cush reviews the news and journal articles from the past week and discusses parent-child rheumatologists pairs.
How Should Patients With Autoimmune Diseases Approach COVID Vaccination?
MedPage Today
Healthcare is a personal and individualized relationship between a provider and patient. Each patient is treated according to their particular symptoms and personal health characteristics.
Social
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/vGt12ul6iy https://t.co/044BScmSYc
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 4 months ago
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
In Memoriam: Dr. K. Frank Austen (1928-2023)
Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95.
https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Why Patients Don't Take Medicines
This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost.
https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta @bella_mehta ( View Tweet )
2 years 6 months ago
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush @RheumNow ( View Tweet )
2 years 6 months ago
We know HCQ adherence is poor in both RA and SLE
>50% in this BC 🇨🇦 cohort
All despite being such an important medicine
What’s super interesting are the trajectories of adherence - and we’d like to understand more about what motivates each group
OP0222 #EULAR2023 @RheumNow https://t.co/rbx1l9T36C
David Liew @drdavidliew ( View Tweet )
2 years 6 months ago
